137 related articles for article (PubMed ID: 20832577)
21. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA
Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073
[TBL] [Abstract][Full Text] [Related]
22. Drug interactions between micafungin at high doses and cyclosporine A in febrile neutropenia patients after allogeneic hematopoietic stem cell transplantation.
Inoue Y; Saito T; Ogawa K; Nishio Y; Kosugi S; Suzuki Y; Kato M; Sakai T; Takahashi M; Miura I
Int J Clin Pharmacol Ther; 2012 Nov; 50(11):831-7. PubMed ID: 22943928
[TBL] [Abstract][Full Text] [Related]
23. [Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation--a retrospective survey by Kanto Study Group for Cell Therapy].
Hagihara M; Kanamori H; Sakai M; Mori T; Nakaseko C; Aotsuka N; Uehara T; Sakura T; Yoshiba F; Kawai N; Tanaka M; Fujisawa S; Ohwada C; Wakita H; Yokota A; Kawamura T; Maruta A; Sakamaki H; Okamoto S;
Rinsho Ketsueki; 2010 Jun; 51(6):390-7. PubMed ID: 20622484
[TBL] [Abstract][Full Text] [Related]
24. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
[TBL] [Abstract][Full Text] [Related]
25. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
26. Disseminated invasive aspergillosis successfully treated with micafungin in a renal transplant recipient.
Wadi J; Al-kawasmeh SI; Kamel MT; AlJayyousi BB
Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):914-8. PubMed ID: 20814131
[TBL] [Abstract][Full Text] [Related]
27. Micafungin: a new echinocandin antifungal.
Joseph JM; Jain R; Danziger LH
Pharmacotherapy; 2007 Jan; 27(1):53-67. PubMed ID: 17192162
[TBL] [Abstract][Full Text] [Related]
28. Interindividual variation of maximal blood levels of tacrolimus after its oral administration in hematopoietic cell transplant recipients.
Yamazaki R; Mori T; Aisa Y; Kato J; Nakamura Y; Nakazato T; Mihara A; Ikeda Y; Okamoto S
Transplant Proc; 2009 Jun; 41(5):1831-3. PubMed ID: 19545738
[TBL] [Abstract][Full Text] [Related]
29. Tacrolimus in hematopoietic stem cell transplantation.
Fortune K; Couriel D
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):835-41. PubMed ID: 19545215
[TBL] [Abstract][Full Text] [Related]
30. Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study.
Kieu V; Jhangiani K; Dadwal S; Nakamura R; Pon D
Transpl Infect Dis; 2019 Feb; 21(1):e13007. PubMed ID: 30295407
[TBL] [Abstract][Full Text] [Related]
31. Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring.
Trifilio SM; Scheetz MH; Pi J; Mehta J
Bone Marrow Transplant; 2010 Aug; 45(8):1352-6. PubMed ID: 19966844
[TBL] [Abstract][Full Text] [Related]
32. Retrospective evaluation of the area over the neutrophil curve index to predict early infection in hematopoietic stem cell transplantation recipients.
Kimura S; Oshima K; Sato K; Sato M; Terasako K; Nakasone H; Kikuchi M; Okuda S; Kako S; Yamazaki R; Tanaka Y; Tanihara A; Nishida J; Kanda Y
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1355-61. PubMed ID: 20457267
[TBL] [Abstract][Full Text] [Related]
33. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.
van Burik JA; Ratanatharathorn V; Stepan DE; Miller CB; Lipton JH; Vesole DH; Bunin N; Wall DA; Hiemenz JW; Satoi Y; Lee JM; Walsh TJ;
Clin Infect Dis; 2004 Nov; 39(10):1407-16. PubMed ID: 15546073
[TBL] [Abstract][Full Text] [Related]
34. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies.
Uberti JP; Silver SM; Adams PT; Jacobson P; Scalzo A; Ratanatharathorn V
Bone Marrow Transplant; 1997 Jun; 19(12):1233-8. PubMed ID: 9208118
[TBL] [Abstract][Full Text] [Related]
35. Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies.
Mori T; Aisa Y; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Yamane A; Ikeda Y; Okamoto S
Transplant Proc; 2007 Jun; 39(5):1615-9. PubMed ID: 17580201
[TBL] [Abstract][Full Text] [Related]
36. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment.
Oran B; Donato M; Aleman A; Hosing C; Korbling M; Detry MA; Wei C; Anderlini P; Popat U; Shpall E; Giralt S; Champlin RE
Biol Blood Marrow Transplant; 2007 Apr; 13(4):469-77. PubMed ID: 17382253
[TBL] [Abstract][Full Text] [Related]
37. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
Cutler C; Li S; Kim HT; Laglenne P; Szeto KC; Hoffmeister L; Harrison MJ; Ho V; Alyea E; Lee SJ; Soiffer R; Sonis S; Antin JH
Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma.
Seropian S; Bahceci E; Cooper DL
Bone Marrow Transplant; 2003 Oct; 32(8):763-9. PubMed ID: 14520419
[TBL] [Abstract][Full Text] [Related]
39. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of micafungin in transplantation recipients.
Forrest GN; Rasetto F; Akpek G; Philosophe B
Transplantation; 2006 Dec; 82(11):1549. PubMed ID: 17164733
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
